Financial Report: Bristol-Myers Squibb

Bristol-Myers Squibb
 
3Q Revenues: $4.1 billion (+9%)  

3Q Earnings: $692 million (loss of $713 million 3Q12)

YTD Revenues: $11.9 billion (-11%)

YTD Earnings: $1.8 billion (+17%)

Comments: U.S. sales increased 1% to $2.0 billion in the quarter. International sales were up 19% to $2.0 billion. Yervoy sales were up 33% to $238 million. Onglyza/Kombiglyze sales were up 19% to $211 million. Sprycel sales grew 20% to $316 million. Orencia sales grew 22% to $375 million. Baraclude sales were $378 million, up 9%. Eliquis, approved in December to prevent strokes caused by an irregular heartbeat, had modest sales of $41 million. Abilify sales were down 16% to $569 million, Avapro/Avalide sales were down 25% to $71 million, and Plavix sales were down 34% to $42 million, impacted by generic competion.